Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MK-8189 by Merck for Schizophrenia: Likelihood of Approval
MK-8189 is under clinical development by Merck and currently in Phase II for Schizophrenia. According to GlobalData, Phase II drugs...
MK-8189 by Merck for Bipolar I Disorder: Likelihood of Approval
MK-8189 is under clinical development by Merck and currently in Phase I for Bipolar I Disorder. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Merck's MK-8189?
MK-8189 is a small molecule commercialized by Merck, with a leading Phase II program in Schizophrenia. According to Globaldata, it...